PET scan test of a new radioactive drug for tumors and inflammation
Part of Cancer, Hormones & metabolism clinical trials.
This Phase 1 study tests whether a new PET imaging tracer (a small amount of radioactive medicine) is safe and how it moves through the body. It’s mainly for adults with cancer who have signs of inflammation or possible immune side effects, so doctors can see what’s happening in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a confirmed cancer (solid or liquid) and you’re receiving immune therapy, or you have suspected immune side effects or inflammation.
- Kidney blood tests must be in the normal range for your age (eGFR 60 or higher).
- Liver blood tests must be in the normal range (bilirubin and enzymes like ALT/AST and alkaline phosphatase).
- If you can become pregnant, you must not be pregnant or nursing, and you must have a negative pregnancy test within 24 hours of the PET scan.
- You must be able to have the PET/CT scan based on weight/size limits and have no known allergy to the tracer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study uses PET/CT scans to see how well a new radioactive tracer (a tiny dose of a special material) highlights solid tumors in the body. It may help researchers learn whether this tracer can better find and track tumor spots seen on standard scans.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
This Phase 1 study tests a new PET/CT imaging tracer to see how well it can detect breast cancer spots in the body. It may help doctors learn where breast cancer is and how imaging could work better in the future.
This trial tests a new type of PET/CT scan that uses a special tracer (called ⁶⁸Ga-FXX489) to help find and diagnose cancers. It is for people who are strongly suspected to have cancer and want to see if this new imaging method can help their doctors learn more about their disease.
This study uses a new imaging agent called [68Ga]-FAPI-JNU to take detailed pictures of tumors with a PET/CT scan. It aims to see how well this tracer works in people with various types of cancer.
This trial tests a PET scan (a type of imaging) that targets cells in the body that help support cancers. It may help doctors better see where cancer-associated cells are located, which could guide future cancer care.
Hear when a new Endocrine Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.